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Although family B G protein-coupled receptors (GPCRs) contain only 15 members, they
play key roles in transmembrane signal transduction of hormones. Family B GPCRs
are drug targets for developing therapeutics for diseases ranging from metabolic to
neurological disorders. Despite their importance, the molecular mechanism of activation
of family B GPCRs remains largely unexplored due to the challenges in expression
and purification of functional receptors to the quantity for biophysical characterization.
Currently, there is no crystal structure available of a full-length family B GPCR. However,
structures of key domains, including the extracellular ligand binding regions and
seven-helical transmembrane regions, have been solved by X-ray crystallography and
NMR, providing insights into the mechanisms of ligand recognition and selectivity, and
helical arrangements within the cell membrane. Moreover, biophysical and biochemical
methods have been used to explore functions, key residues for signaling, and the kinetics
and dynamics of signaling processes. This review summarizes the current knowledge
of the signal transduction mechanism of family B GPCRs at the molecular level and
comments on the challenges and outlook for mechanistic studies of family B GPCRs.
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INTRODUCTION
G protein-coupled receptors (GPCRs), which form the largest protein superfamily of the vertebrate
genome, play an important role in signal transduction by detecting extracellular stimuli and
activating intracellular downstream pathways (Figure 1; Fredriksson et al., 2003). All GPCRs share
a common seven-transmembrane topology, and mediate cellular responses through interactions
with a variety of extracellular signals. These extracellular signals range from photons and small
molecules to hormones and proteins, indicating the structural and functional diversity of over
800 different GPCRs (Lagerstrom and Schioth, 2008). Despite the diversity, GPCRs share a
general mechanism of activation that begins with ligand binding, which causes conformational
rearrangements in the seven-transmembrane (7TM) domain that activate the G protein in
the cytoplasmic region. G protein activation triggers various signaling cascades to mediate
physiological processes. Since the ligand binding sites are highly specific, GPCRs have been heavily
exploited as drug targets. They are the targets for over 40% of the current pharmaceutical drugs on
the market with an estimated global sales of∼$85 billion (Stevens et al., 2013).
Although most drugs developed against GPCRs target family A receptors, family B GPCRs
are becoming increasingly attractive drug targets, especially for treatment of metabolic diseases
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FIGURE 1 | A comparison of GPCRs in family B with GPCRs in the other four families. Family B GPCRs detect peptide hormones and have a relatively large
extracellular N-terminus (∼120 amino acids) with a conserved structural fold stabilized by cysteine bonds. Family A GPCRs bind a wide range of diverse ligands in the
transmembrane region and have a small extracellular domain. Family C receptors have a large extracellular N-terminal ligand-binding region in the “Venus flytrap” fold
for ligand binding with a conserved disulfide linkage to form a dimer. The adhesion and frizzled families have GPCR-like transmembrane-spanning regions fused
together with one or several functional N-terminal domains. Ligands are shown in red. Scissors in the adhesion family indicate the autoproteolysis-inducing domain.
(Tautermann, 2014). The 15 family B GPCRs for various
peptide hormones are grouped into subfamilies based on their
physiological roles, including insulin secretion, vasodilation,
regulation of Ca2+ homeostasis, and cardiac contractility
(Table 1). Nearly all family B GPCRs have been validated as
drug targets for diseases, such as cancer, osteoporosis, diabetes,
cardiovascular disease, neurodegeneration, and migraine
(Table 1; Archbold et al., 2011). However, it has been challenging
to identify small-molecule therapeutics to target this family,
with only a few peptide agonists approved by the FDA as drugs.
Most of these agonist drugs are derivatives of the family B
cognate peptide ligands (Table 1). The challenge of identifying
conventional small-molecule drugs lies in the lack of molecular
information to locate druggable binding sites for in silico drug
design and screening. Nevertheless, the recently reported and
first available crystal structures of the transmembrane domain
(TMD) of two family B GPCRs are expected to advance the
development (Hollenstein et al., 2013; Siu et al., 2013).
Compared to GPCRs in other families (Figure 1), family B
GPCRs have a relatively large N-terminus that is ∼120 amino
acids long. Their N-terminus shares a similar fold stabilized
by three conserved disulfide bridges, which construct part of
the binding site for ligand recognition. While GPCRs in other
families have a wide range of ligands, such as small molecules,
ions, lipids, and proteins, all family B receptors bind peptide
hormones, modulating physiological processes such as calcium
homeostasis and regulation of blood glucose, as summarized in
Table 1.
Ligands that activate family B GPCRs are peptide hormones
with a length of 26 to 114 amino acids. Most ligands of
family B GPCRs lack ordered structure in aqueous solutions
but form α-helical fragments upon binding to their cognate
receptors or under structure-inducing conditions such as in the
presence of organic solvents, lipids, or upon crystallization (as
reviewed in Parthier et al., 2009). It is widely accepted that
the peptide hormones interact with family B GPCRs following
the “two-domain” model, in which the peptide hormone’s C-
terminus binds to their cognate receptor’s N-terminal domain
and the N-terminus binds to the receptor’s juxtamembrane
and transmembrane domains (Figure 2). Such binding leads to
conformational changes in the receptor’s cytoplasmic domain to
active a G protein to trigger a downstream signaling process
(Pal et al., 2012).
Tremendous progress has been made in the past 15
years to obtain structural information about GPCRs; however,
knowledge about the structure of family B GPCRs is still
very limited. Most of the previous structural studies of
GPCRs focus on family A receptors, with over a hundred
solved crystal structures of over 20 different receptors. For
family B GPCRs, most efforts were focused on obtaining the
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TABLE 1 | Summary of Family B GPCR physiology and drugs (Hoare, 2005; Archbold et al., 2011; Bortolato et al., 2014).
Receptor(s) Ligands Physiological functions Disease(s) Available drugs
CALCITONIN RECEPTOR FAMILY
Calcitonin receptor (CTR) Calcitonin Ca2+ homeostasis Osteoporosis Miacalcin, Fortical
Amylin receptors (AMY1, AMY2,
AMY3 )
Amylin Energy homeostasis and body
fluid balance
Diabetes/obesity Pramlintide
Amyloid-beta (Aβ) protein
Calcitonin gene-related peptide
receptor (CGRP receptor)
α-calcitonin gene-related peptide
(α-CGRP)
Vasodilation and nociception Migraine
ß-CGRP
Adrenomedullin receptors (AM1,
AM2 )
adrenomedullin 1 Vasodilation Cardiovascular
disease, cancer
adrenomedullin 2
GLUCAGON RECEPTOR FAMILY
Glucagon receptor (GCGR) Glucagon Regulation of blood glucose Diabetes Glucagon
Glucagon-like peptide 1 receptor
(GLP-1R)
Glucagon-like peptide 1 (GLP-1) Insulin and glucagon secretion Diabetes Exenatide,
Lixisenatide,
Liraglutide, Albiglutide,
Dulaglutide
Glucagon-like peptide 2 receptor
(GLP-2R)
Glucagon-like peptide 2 (GLP-2) Gut mucosal growth Short bowel
syndrome, Crohn’s
disease, osteoporosis
Teduglutide
Gastric inhibitory polypeptide
receptor (GIPR)
Gastric inhibitory polypeptide (GIP) Insulin secretion, fatty acid
metabolism
Diabetes/obesity
CORTICOTROPIN-RELEASING HORMONE RECEPTORS
Corticotropin-releasing factor
receptor 1 (CRF1R)
Corticotropin-releasing factor (CRF) Release of ACTH and central
stress responses
Stress, inflammatory
bowel syndrome
Corticorelin
Urocortin I (Ucn1)
Corticotropin-releasing factor
receptor 2 (CRF2R)
CRF Central stress responses,
cardiac contractility, hearing
Cancer, heart failure,
hypertension
Urocortin II (Ucn2)
Urocortin III (Ucn3)
PARATHYROID HORMONE RECEPTORS
Parathyroid hormone 1 receptor
(PTH1R)
Parathyroid hormone (PTH) Ca2+ homeostasis Osteoporosis,
hypoparathyroidism
Teriparatide, Preotact
Parathyroid hormone-related protein
(PTHrP)
Developmental regulator
Parathyroid hormone 2 receptor
(PTH2R)
PTH Hypothalamic secretion,
nociception
Nociception
Tuberoinfundibular peptide of 39
residues (TIP39)
VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTORS
Vasoactive intestinal polypeptide
receptor 1 (VPAC1R)
Vasoactive intestinal polypeptide
(VIP)
Vasodilation, neurotransmission,
neuroendocrine functions
Inflammation,
neurodegeneration
PACAP
Vasoactive intestinal polypeptide
receptor 2 (VPAC2R)
VIP Vasodilation, neurotransmission
neuroendocrine functions
Inflammation,
neurodegeneration
PACAP
OTHERS
Pituitary adenylate
cyclase-activating polypeptide
type I receptor (PAC1R)
Pituitary adenylate cyclase-activating
polypeptide (PACAP)
Neurotransmission
neuroendocrine functions
Neurodegeneration
nociception, glucose
homeostasis
Growth-hormone-releasing
hormone receptor (GHRHR)
Growth hormone-releasing hormone
(GRHR)
Release of growth hormone Dwarfism, HIV-related
lipodystrophy
Tesamorelin,
Sermorelin, CJC-1295
Secretin receptor (SCTR) Secretin Pancreatic secretion Autism,
schizophrenia,
duodenal ulcers,
gastrinoma
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FIGURE 2 | Two-domain binding model of family B GPCRs. The
C-terminal region of the peptide ligand interacts with the N-terminal domain of
the receptor (yellow), allowing the N-terminus of the peptide ligand to interact
with the juxtamembrane and TMD (red) to activate the receptor.
crystal structures of the N-terminal ligand-binding domains
(Grace et al., 2007; Parthier et al., 2007; Sun et al., 2007; Pioszak
and Xu, 2008; Pioszak et al., 2008, 2009; Runge et al., 2008; Pal
et al., 2010; Kumar et al., 2011) until Hollenstein et al. and Siu
et al. reported the crystal structures of transmembrane domain
of two family B receptors in 2013 (Table 2; Hollenstein et al.,
2013; Siu et al., 2013). Although this structural information has
provided insights into the structural and functional diversity
of family B GPCRs, there is still no full-length structure of
family B GPCRs available. Hence, how the extracellular ligand
binding domain and transmembrane domain of family B GPCRs
cooperate to transduce a signal across the cell membrane upon
ligand binding remains largely unknown. Here, we will review
the recent progress in addressing this question by surveying
the structural, biochemical, and biophysical studies of various
domains of family B GPCRs (Figure 3).
In this review, we will focus on how the extracellular,
transmembrane, and cytoplasmic domains of family B
GPCRs (Figure 3) carry out the functions of peptide hormone
recognition and signal transduction across the cell membrane.
We will also discuss how this signaling process is modulated
by accessory proteins (Figure 3). On the basis of the two-
domain model (Figure 3), we will first discuss the recognition
and binding of peptide ligands in the extracellular domains,
including the N-terminal and juxtamembrane domains (Section
Extracellular Domain: Ligand Binding). Then, we will discuss
ligand interactions and ligand-induced helical movements in
the transmembrane domain (Section Transmembrane Domain:
Ligand-induced Helical Movements). Subsequently, we will
review how activated family B GPCRs couple to G proteins in
cytoplasmic domain (Section Cytoplasmic Domain: G Protein
Coupling). We will also provide a brief overview of accessory
proteins that regulate the activity of family B GPCRs (Section
Interaction with Accessory Proteins). Finally, we will conclude
with a summary and outlook of mechanistic studies of family
B GPCRs (Section Challenges and Outlook). Through these
discussions, we hope to provide a systematic review of the
current understanding of molecular activation mechanism of
family B GPCRs.
EXTRACELLULAR DOMAIN: LIGAND
BINDING
The extracellular domain of family B GPCRs contains two
parts: the N-terminal domain and the juxtamembrane domain
(Figure 3). The latter is composed of three extracellular loops
and the peptide fragment at the junction between the N-terminal
domain and helix 1. The N-terminal and juxtamembrane
domains work together to sense the peptide hormones in the
initial step of signal transduction. Solved structures of the
extracellular domains bound to their cognate peptide ligands
(Table 2) provide crucial information about mechanisms of
ligand recognition and selectivity. In this section, we will first
discuss the two-domain binding model and then the specific
molecular interactions of the ligands with the N-terminal and
juxtamembrane domains of the receptors.
Experimental Evidence for the Two-domain
Binding Model
The two-domain binding model, as described in Figure 2, has
been widely used to describe the binding of peptide hormones
to family B GPCRs (as reviewed in Pal et al., 2012), which is
supported by kinetic and reciprocal chimera studies.
In the kinetic studies, Förster Resonance Energy Transfer
(FRET) experiments of parathyroid hormone (PTH) binding
to parathyroid hormone receptor 1 (PTH1R) showed the first
high affinity binding step occurs quickly (∼0.10 s) and the
second activation step slowly (∼1 s) (Vilardaga et al., 2011).
Although similar kinetic data from othermembers of the family is
currently unknown, the two-step kinetics of receptor binding and
activationmay potentially be conserved in other family B GPCRs.
The two-domain model is also supported by two
representative chimera studies, in which one GPCR is created
from pieces of two different receptors and one ligand from
pieces of the two corresponding cognate peptide ligands
(Figure 4A). In the first study, Bergwitz et al. designed a
chimeric system using calcitonin receptor (CTR) and PTH1R,
and determined the activation of the chimeric receptors by
quantifying cAMP accumulation after treatment with two
chimeric peptide hormones (Bergwitz et al., 1996). The chimeric
peptide hormones with calcitonin at the C-terminus most
strongly activated the chimeric receptor with CTR’s N-terminal
domain. Similarly, the peptide ligand with the PTH C-terminus
most strongly activated the chimeric receptor with the PTH1R’s
N-terminal domain (Bergwitz et al., 1996). In the second study,
Unson et al. mutated regions of the N-terminal domain and
juxtamembrane domain of the glucagon receptor (GCGR)
to the corresponding regions of the secretin receptor (SCTR,
Figure 4B; Unson et al., 2002). Chimeric receptors containing
secretin residues for the N-terminal domain residues 126–137
or the extracellular loop 1 residues 206–219 showed the largest
decrease in both ligand binding and receptor activation upon
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TABLE 2 | Structures (X-ray or NMR) available for family B GPCR domains.
Receptor(s) Domain PDB ID Ligand used Resolution (Å)
CALCITONIN RECEPTOR FAMILY
CGRP receptor (ter Haar et al., 2010) N-terminal LBD complex (CLR
23–133 + RAMP1 26–117)
3N7P N/A 2.80
N-terminal LBD complex (CLR
23–133 + RAMP1 26–117)
3N7R telcagepant (a
small
molecule
antagonist)
2.90
N-terminal LBD complex (CLR
23–133 + RAMP1 26–117)
3N7S olcegepant (a
small
molecule
antagonist)
2.10
AM1 receptor (Kusano et al., 2012) N-terminal LBD complex (CLR
23–136 + RAMP2 39–139)
3AQF No ligand 2.60
GLUCAGON RECEPTOR FAMILY
Glucagon receptor N-terminal LBD 28–123 4ERS (Koth et al., 2012) No ligand 2.64
N-terminal LBD 29–123 4LF3 (Mukund et al., 2013) No ligand 2.73
TMD 123–434 4L6R (Siu et al., 2013) N/A 3.30
GLP-1R N-terminal LBD 24–145 3IOL (Underwood et al., 2010) GLP-1(7–37) 2.10
N-terminal LBD complex 24–145 3C5T (Runge et al., 2008) Exendin-4(9–
39)
2.10
N-terminal LBD 24–145 3C59 (Runge et al., 2008) (SeMet14,21)-
exendin-4(9–
39)
2.30
GIPR N-terminal LBD 24–138 4HJ0 (Ravn et al., 2013) Antibody 3.00
N-terminal LBD 29–138 2QKH (Parthier et al., 2007) GIP (1–42) 1.90
CORTICOTROPIN-RELEASING HORMONE RECEPTORS
CRF1R N-terminal LBD 24–119 3EHS (Pioszak et al., 2008) N/A 2.76
N-terminal LBD 24–119 3EHT (Pioszak et al., 2008) CRF27–41 3.40
N-terminal LBD 24–119 3EHU (Pioszak et al., 2008) CRF22–41 1.96
TMD 104–373 4K5Y (Hollenstein et al., 2013) Antagonist:
CP-376395
(small
molecule)
2.98
CRFR2α N-terminal LBD 3–154 3N96 (Pal et al., 2010) Urocortin-1
(25–40)
2.75
N-terminal LBD 3–154 3N95 (Pal et al., 2010) Urocortin-2
(23–38)
2.72
N-terminal LBD 3–154 3N93 (Pal et al., 2010) Urocortin-3
(23–38)
2.50
CRFR-2β N-terminal LBD 15–133 1U34 (Grace et al., 2004) N/A N/A NMR
N-terminal LBD 39–133 2JNC (Grace et al., 2007) No ligand N/A NMR
N-terminal LBD 39–133 2JND (Grace et al., 2007) Astressin N/A NMR
PARATHYROID HORMONE RECEPTORS
PTH1R N-terminal LBD 29–187 3L2J (Pioszak et al., 2010) N/A 3.24
N-terminal LBD 29–187 3C4M (Pioszak and Xu, 2008) PTH(15–34) 1.95
N-terminal LBD 29–187 3H3G (Pioszak et al., 2009) PTHrP(12–34) 1.94
VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTORS
VIP2R N-terminal LBD 26–118 2X57 N/A 2.10
Others
PACAP receptor N-terminal LBD 22–143 2JOD (Sun et al., 2007) PACAP (6–38) N/A NMR
N-terminal LBD 3N94 (Kumar et al., 2011) PACAP (6–38) 1.80
GHRHR N-terminal LBD 34–123 2XDG N/A 1.95
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FIGURE 3 | Structural model for family B GPCRs. Three domains in family B GPCRs: (1) the extracellular domain, comprising of the N-terminal domain and the
juxtamembrane domain, (2) the transmembrane domain (TMD), and (3) the cytoplasmic domain. Three accessory proteins: (1) receptor activity modifying proteins
(RAMPs), (2) Na/H exchange regulatory factors (NHERFs), (3) calmodulin (CaM). Purple: a family B GPCR, yellow: three conserved disulfide bonds, blue: a
heterotrimeric G protein, and red: accessory proteins.
binding to the glucagon peptide (Figure 4B). Interestingly,
a chimeric GCGR/SCTR with SCTR residues in extracellular
loop 1 residues 220–231 showed no change in binding affinity
to the glucagon peptide, but a decrease in receptor activation
(Unson et al., 2002), further elucidating a specific region of the
juxtamembrane domain involved in the second binding step and
receptor activation, supporting the two-domain model.
Ligand Binding Interactions with the
N-terminal Domain
The first step in the two-domain model—ligand binding to
the N-terminus of receptors—is strongly supported by crystal
structures of nine different ligands bound to the N-terminal
domain of their respective receptors (Table 2 and Figure 5;
Grace et al., 2004; Parthier et al., 2007; Sun et al., 2007;
Pioszak and Xu, 2008; Pioszak et al., 2008, 2009; ter Haar
et al., 2010; Underwood et al., 2010; Koth et al., 2012). These
crystal structures reveal that the N-terminal domains contain a
conserved three-layered α-β-βα fold (Figure 6) with the helical
segment of the peptide hormone primarily interacting in the
middle layer as if a “hotdog in a bun” (Figures 5A–C, 6) (Parthier
et al., 2009; Pal et al., 2012). Six conserved cysteine residues
form three interlayer disulfide bonds that stabilize the α-β-β
α fold (Figure 6). Additional hydrophobic packing interactions
and hydrogen bonds stabilize the second and third layers (as
reviewed in Hollenstein et al., 2014). Sequence conservation
indicates the importance of these stabilizing interactions, which
likely involve five mostly conserved residues: Asp113, Trp118,
Pro132 and Gly152, and Trp154 (PTH1R residues, pink in
Figures 6A,B; Pioszak and Xu, 2008). These conserved residues
and the structural similarities of the three-layered fold form a
structural foundation for the two-domain binding model.
However, there are a few differences between the structures of
the various receptor N-terminal domains, which likely provide
ligand specificity. For example, Grace et al. determined the
structure of the N-terminal domain of CRF2R (Figure 5E) using
NMR and found the absence of the N-terminal α-helix that
is conserved in the majority of the other crystal structures
(Figure 5; Grace et al., 2004). More recent crystal structures
of the N-terminal domains of CRF1R show the N-terminal
α-helix tends to be shorter than the same region in other
family B receptors (Figure 5D compared to Figures 5A–C,F–I;
Pioszak et al., 2008). These structural characteristics cause the
peptide hormone to interact with the N-terminal domain at
a slightly shifted location compared to the other receptors
including GLP-1R, PTH1R, and GIPR (Figures 5D,F compared
to Figures 5A–C). Sequence alignment of the 15 Family B GPCRs
supports the difference in the structure of the N-terminal α-helix
as it shows a limited number of conserved residues in addition
to the six conserved cysteine residues in the N-terminal domain
(Pioszak et al., 2009).
Aside from structural data, biochemical studies further
support the two-domain binding model (summarized in
Supplementary Table S1). The reciprocal chimera studies that
support the “hotdog in a bun” model also implicate the middle
layer of the N-terminal domain in peptide hormone binding
(Bergwitz et al., 1996). In addition, results from alanine scanning
studies further determined the N-terminal domain residues
necessary for ligand binding (Barwell et al., 2010). These alanine-
scanning studies test receptor constructs with mutations in
specific regions of a receptor for ligand binding affinity using
radiolabeled ligands and for receptor activation using cell based
cAMP accumulation assays. Depending on the location of the
mutations, they might affect only the ligand binding affinity (the
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FIGURE 4 | Ligand interactions with the juxtamembrane domain. (A)
General chimeric receptor made from components of two receptors: one
receptor’s extracellular domain and C-terminus of the ligand (teal) and the
other receptor’s transmembrane domain and N-terminus of the ligand (purple).
(B) Binding studies of a chimeric GCGR (purple) with regions of SCTR (teal)
implicate extracellular loop 1 and the middle region of the N-terminal domain in
high affinity ligand binding (Bergwitz et al., 1996; Unson et al., 2002). (C)
Photoaffinity cross-linking studies with Bpa show interactions between colored
regions of secretin and the corresponding colored portion of SCTR. the long
N-terminal fragment of secretin interacts deep in the transmembrane region of
SCTR (Dong et al., 2002, 2004, 2008, 2011b, 2012). (D) Interactions between
VIP and VPAC1R as determined by mutations and photoaffinity cross-linking
studies show similar interaction regions as secretin/SCTR (Couvineau et al.,
1995; Du et al., 1997; Tan et al., 2003, 2006; Ceraudo et al., 2008).
first binding event), only the receptor activation (the second
binding event), or both responses. For example, mutations in
the N-terminal α-helix (red in Figure 6A) of the calcitonin gene
related peptide (CGRP) receptor show that mutating Leu32 and
Leu34 to alanine decreases binding affinity (the first binding
event) without decreasing cAMP production (the second binding
event; Banerjee et al., 2006).
A complementary approach to uncovering the ligand binding
determinants involves alanine scanning of the peptide hormone
residues (Adelhorst et al., 1994; Nicole et al., 2000; Igarashi et al.,
2002a,b; Bourgault et al., 2009; Dong et al., 2011b, 2013; Watkins
et al., 2013). Figure 6 shows important results from alanine
scanning studies of PTH and gastric inhibitory polypeptide
(GIP). The residues labeled in orange in the peptide hormones
significantly decrease binding affinity when mutated to alanine,
confirming their importance in ligand binding (Parthier et al.,
2007; Pioszak and Xu, 2008). In addition, one recent study of
the secretin peptide with ligand binding and activation assays
compared results from five receptors and foundmanyN-terminal
residues of the hormones are important for both ligand binding
and biological activity, while C terminal residues tend to be
important for binding affinity (Figure 7; Dong et al., 2011b). In
combination with the crystal structures and N-terminal domain
mutations, this provides a more complete view of the high affinity
binding of the C-terminal region of the peptide to the N-terminal
domain, the first step of the two-domain binding model.
Ligand Binding to the Juxtamembrane
Domain
The second step of the two-domain binding model involves
interactions between the N-terminus of the peptide and the
juxtamembrane domain of the receptor, which has been less
studied mainly due to the lack of structural information of
full-length family B GPCRs. Photoaffinity cross-linking has
been commonly used to probe these interactions and elucidate
specific contacts between the peptide ligand and the receptor.
In the photoaffinity studies, p-benzoyl-L-phenylalanine (Bpa) is
incorporated in the hormone ligands as a probe. Upon exposure
to UV light, the Bpa residue is cross-linked with the residues
in the receptor within 9 Å. Hence, the site of interaction
can then be determined by proteolytic Edman degradation
followed by autoradiography (Miller et al., 2011). Photoaffinity
studies on GLP-1R, SCTR, and PTH1R have identified important
receptor/ligand interactions (Figure 4; Zhou et al., 1997; Chen
et al., 2009; Dong et al., 2011a; Miller et al., 2011). For example,
Dong et al. investigated secretin/SCTR interactions, with five
different Bpa label positions and found the labels at the C-
terminal end of the peptide (residues 15, 20, 24, 25) interacted
with the N-terminal domain (blue, Figure 4C), while labels at the
N-terminus of the peptide interact with extracellular loop 1 and
regions of the transmembrane domain (red, Figure 4C; Dong
et al., 2011a). The interactions identified support the second
step of the N-terminal region of the ligand interacting with the
juxtamembrane domain in the two-domain binding model.
Moreover, mutagenesis studies of the extracellular loops of
receptors also show the importance of the juxtamembrane
domain in ligand binding and receptor activation. For instance,
Gkountelias et al. studied CRF1R. They mutated residues in all
three of the extracellular loops and found that two mutations in
extracellular loop 2 (Phe260 and Trp259) decreased both ligand
binding affinity and receptor activation (Gkountelias et al., 2009).
In addition, an alanine scanning study of the calcitonin receptor
implicated extracellular loop 1 in ligand binding (Barwell et al.,
2011). These results suggest that the juxtamembrane domain is
involved in not only ligand binding but also receptor activation
in the two-domain binding model.
A final important factor in ligand binding to the
juxtamembrane domain is the structure of the N-terminal
region of the peptide hormone. By analyzing the sequence
of the N-terminal region of the peptide ligands, Neumann
et al. identified conserved helix-capping motifs, which provide
additional hydrogen bonds for stabilizing the configuration of
the first four amino acids in the α-helices (Neumann et al., 2008).
Based on the analysis, they proposed that this helix-capping
can play an important role in receptor specificity and formation
of α-helix in the peptide ligands upon binding to receptors
(Parthier et al., 2009). These proposed functional roles of the
helix-capping motifs may be very important and are worth
further experimental validation.
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FIGURE 5 | Available crystal structures of the N-terminal domains of nine family B GPCRs. (A) GLP-1 bound to GLP1R (Underwood et al., 2010). (B) PTH
bound to PTH1R (Pioszak and Xu, 2008). (C) GIP bound to GIPR (Parthier et al., 2007). (D) CRF bound to CRF1R (Pioszak et al., 2008). (E) Astressin bound to
CRF2R (Grace et al., 2004). (F) PACAP bound to PACAPR (Sun et al., 2007). (G) VPAC2R (PDB ID 2X57). (H) GCGR (Koth et al., 2012). (I) CLR (ter Haar et al., 2010).
FIGURE 6 | The three-layered α-β-βα fold for the N-terminal domain
of family B GPCRs. (A) Schematic of the α-β-βα fold with conserved
residues (pink) and disulfide bonds (yellow). (B) A representative crystal
structure showing the α-β-βα fold, disulfide bonds and conserved residues
(PDB 2QKH Parthier et al., 2007). (C,D) Important residues in peptide
ligands for binding to PTH1R (C) and GIPR (D) identified by crystal
contacts and mutagenesis studies. Important residues contacts are shown
as sticks. Color codes: the top (red), middle (green), and bottom (blue)
layers, three conserved disulfide bonds (yellow), conserved residues
stabilizing the three-layer fold (pink), ligand residues important in binding
affinity (orange; Pioszak and Xu, 2008).
Aside from specific interactions between the peptide hormone
and the extracellular domain, other factors influence ligand
binding affinity and specificity for a given receptor. One
such situation occurs when a receptor binds more than
one native ligand, with each ligand eliciting a distinct
physiological response. For instance, PTH1R interacts with two
native ligands, PTH and PTHrP. While both peptides initiate
cAMP accumulation inside cells, continuous administration
of individual ligands induces opposite physiological effects,
with PTH increasing bone resorption and PTHrP stimulating
bone formation (Mannstadt et al., 1999). Nonetheless, how
the receptors distinguish between these different pathways
remains unclear. In addition, allosteric effects from regions
of the receptors not directly involved in ligand binding add
complexity to the molecular mechanism of ligand recognition
in family B GPCRs. For example in GLP-1R, a mutation across
the membrane in intracellular loop 3 (ICL3) decreases the
binding affinity of the GLP-1 ligand by 10-fold (Heller et al.,
1996). Further investigation into allosteric effects is likely to
uncover new mechanisms of ligand selectivity in family B
GPCRs.
Both structural and biochemical results greatly increase the
understanding of the interactions of the peptide hormone
binding to the N-terminal and juxtamembrane domains,
formulating the well accepted two-domain binding model.
Although the process of peptide-hormone binding to the
receptor is the most studied event of the signaling cascades,
identifying interactions is only part of the story. Very little
is known about how those interactions cause conformational
changes that propagate the signal to the cytoplasmic side of the
receptor, resulting in activation of G proteins. In the following
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FIGURE 7 | Structure based alignment of family B GPCR ligands from
the center of the α-helix (red). The blue and green lines show residues that
decrease ligand-binding affinity when mutated. Blue lines indicate mutations
that decrease ligand binding without specifying the region of the receptor
where the interaction occurs. Green lines indicate residues implicated in ligand
binding that interact with the N-terminal domain as confirmed by crystal
structures. The data for the calcitonin receptor comes from cross-linking
experiments (Adelhorst et al., 1994; Igarashi et al., 2002b; Perret et al., 2002;
Dong et al., 2004; Pham et al., 2004, 2005; Parthier et al., 2007; Sun et al.,
2007; Pioszak and Xu, 2008; Pioszak et al., 2008, 2009; Bourgault et al.,
2009).
section, we will summarize the current understanding of such
conformational changes in the transmembrane region of family
B GPCRs.
TRANSMEMBRANE DOMAIN:
LIGAND-INDUCED HELICAL MOVEMENTS
The transmembrane domain (TMD) of family B GPCRs serves
as the bridge for communication between extracellular ligand
binding and the G-protein coupling at cytoplasmic regions.
Ligand binding causes conformational rearrangements within
the TMD, which triggers downstream signaling cascades via
G protein activation. The structures of the ligand-bound
N-terminal domain of many family B GPCRs have been
reported. In 2013, TMD crystal structures of two family B
GPCRs were published, (Hollenstein et al., 2013; Siu et al.,
2013) a major step forward in the field. However, the
structure of a full-length family B GPCR remains largely
unknown. As a result, the mechanistic understanding of
conformational rearrangements in the activation process of
family B GPCRs had long been stagnant. In this section, we
will analyze the TMD structures of two family B GPCRs in
comparison to family A GPCRs. We will focus on the ligand
interactions within the TMD regions, as well as the potential of
designing small-molecule modulators for binding to the TMD
region of family B GPCRs. Finally, we will evaluate possible
conformational changes of the TMD upon activation in light
of both the new structural information and prior biochemical
studies.
Structural Comparison of CRF1R and
GCGR and Key Residues Involved
To date, crystal structures of the TMD of two family B GPCRs
are available. They include human corticotropin-releasing factor
receptor 1 (CRF1R) in complex with the small-molecule
antagonist CP-376395 at 3.0 Å resolution, (Hollenstein et al.,
2013) and human glucagon receptor (GCGR) in complex
with the antagonist NNC0640 at 3.4 Å resolution crystalized
with apocytochrome b562RIL from E.coli fused at the N-
terminus (Siu et al., 2013). CRF1R and GCGR share about
30% sequence identity within the TMD (Figure 8). Here, we
compare their structural characteristics with respect to family A
GPCRs.
As expected, the hallmark 7TM helical bundles of family
A GPCRs are observed in both CRF1R and GCGR. Figure 9
presents the superimposition of the crystal structures of the
7TM of the two family B GPCRs and a representative family
A GPCR [dopamine D3 receptor (Chien et al., 2010)] in their
inactive conformations. While the structural conservation in the
two family B GPCRs appears highest among the cytoplasmic
half of TM helices, the extracellular half shows more divergence.
This suggests each receptor has a characteristic, highly selective
ligand-binding site. Also, it is worth noting that GCGR has an
extended, long TM1 as compared to family A GPCRs, which
is seen in the sequence of most family B GPCRs (Figure 8).
This helical fragment, extending into the extracellular and
juxtamembrane domains, may play an important role in ligand
binding and signal transduction of the transmembrane region.
On the other hand, the structural similarity of the cytoplasmic
half of the helices suggests conformational rearrangements
associated with G protein binding upon activation may be more
conserved because a large number of GPCRs interact with
the same, less diverse G proteins. The TMD structures of the
two family B GPCRs show that the extracellular sides of the
transmembrane domains assume a “V” shape that is more open
toward the extracellular side than any of the family A GPCR
structures (Figure 9). The “V” shape conformation presents
a large, solvent-filled cavity accessible to extracellular ligand
binding. One side of the “V” shape is formed by TM1, TM6,
and TM7, and the other side is by TM2–TM5 (Figure 9A). These
bundles of helices are similar to those observed in rhodopsin and
other family A receptors (Crocker et al., 2006).
Turning to TM1, TM6, and TM7 on one side of the “V”
shape, TM6 and TM7 of both receptors point away from the
center of the helical bundle. In CRF1R, this region is even
further away from the center of the helical bundle compared to
GCGR. Similar interhelical interactions in CRF1R and GCGR
contribute to the stabilization of the extracellular half of the
transmembrane domain. In CRF1R, TM1 packs against and
stabilizes a kink in TM7 at Gly3567.50b/7.46 (Figure 10 Box 1)
through formation of hydrogen bonds between highly conserved
Ser1301.50b/1.46 on TM1 and Phe3577.51b/7.47 and Ser3537.47b/7.43
on TM7 (Figure 10B). Although the same interaction is not
clearly observed in the crystal structure of GCGR, the conserved
residues Ser1521.50b/1.46 on TM1 and Gly3937.50b/7.46 on TM7
may perform a similar role, resulting in the kinked structure in
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FIGURE 8 | Structural-based sequence alignment of the transmembrane helices and helix 8 of family B GPCRs. For every position in the transmembrane
region, the most conserved residue is color coded with its percent consensus (color coded from cyan 20% to red 100% consensus). The residues in transmembrane
helices are numbered according to Wootten numbering scheme (Box 1 in Figure 10).
TM7 that causes the extracellular halves of TM6 and TM7 to tilt
away. The kink in TM7 is similar to the one revealed in the crystal
structures of family A GPCRs situated at the highly conserved
NPxxY motif. In addition, the TM6 and TM7 regions of both
receptors exhibit high temperature factors, indicating structural
flexibility and possible movements upon ligand binding and
activation.
On the other side of the “V” shape, TM4 in both receptors
contains the highly conserved family B GPCR sequence motif
of GWGxP. Although the TM4 helices of the two receptors do
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FIGURE 9 | Structural alignment of CRF1 (gold, PDB ID 4K5Y) and GPCR (blue, PDB ID 4L6R). (A) The receptors are viewed from two different angles from
within the membrane. The TM helices are labeled and comprise the two halves of the V-shape open configuration. (B) Structural comparison of the two family B
GPCRs with a family A GPCR, dopamine D3 receptor (gray, PDB ID 3PBL), in its inactive form. Individual TM helices are shown after superposition of the three
receptors.
not superimpose perfectly (Figure 9), this GWGxPmotif plays an
important structural role in stabilizing the configuration of TM2,
TM3, and TM4 (Hollenstein et al., 2014). In CRF1R, TM4 bends
at Gly2354.49b/4.49 and points Trp2364.50b/4.50 toward TM2 and
TM3 within the conserved motif. Hydrogen bonds are formed
between Trp2364.50b/4.50 and Asn1572.52b/2.45 on TM2 and
Tyr1973.38b/3.34 on TM3 (Figure 10C). In GCGR, while residues
Gly2714.49b/4.49 and Trp2724.50b/4.50 on TM4, Asn1792.52b/2.45
on TM2 and Tyr2333.38b/3.34 on TM3 are conserved, hydrogen
bonds are formed differently between Trp2724.50b/4.50 and
Tyr2333.38b/3.34 (Figure 10C). The inconsistency may result from
the ambiguous electron density in the TM4 region of GCGR.
Nonetheless, given the high resolution across this region in
CRF1R, the observed interactions associated with the GWGxP
motif in CRF1R may exist in all family B GPCRs (Hollenstein
et al., 2013, 2014).
Moving from the extracellular side to the cytoplasmic side
of the transmembrane domains, His2.50b/2.43 on TM2 and
Glu3.50b/3.46 on TM3 are in close proximity in both structures,
and their interaction is proposed to be functionally and
structurally important (Schipani et al., 1995, 1997; Heller et al.,
1996; Hjorth et al., 1998; Vohra et al., 2013; Wootten et al., 2013).
Toward the end of TM7, Tyr4007.57b of GCGR forms hydrogen
bonds with residues Glu2453.50b on TM3 and Thr3516.42b on
TM6 and is positioned in a similar conformation to family
A GPCRs that is associated with activation (Rasmussen et al.,
2011). Interactions at the equivalent Tyr3637.57b of CRF1R
were not clearly present in the crystal structure, possibly
because helix 8 was removed in the construct, which may
have affected the orientation and length of TM7. In fact, this
tyrosine residue is conserved among family B GPCRs (Figure 8),
and is predicted to be associated with the activation and
interaction with the G protein (Vohra et al., 2013; Wootten et al.,
2013), as discussed later in Section Activation and Allosteric
Transition.
Two additional structural features that may be functionally
important in the GCGR structure include the additional N-
terminal helical turns of TM1 extending far into the extracellular
space and an unusually long helix 8 connected to TM7 (Figure 9).
Even though these structural features may result from artifacts
during crystallization, the extension of TM1 may be important
in restricting the position of the N-terminal domain for ligand
binding. In addition, the unusually long helix 8 connecting to
TM7 bends slightly toward the cytoplasm and has its N-terminal
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FIGURE 10 | Structural features of family B GPCRs. Conserved structural features in CRF1R (yellow) and GCGR (blue) are highlighted within the superposition of
the two structures. (A) The receptors viewed from the extracellular side; (B,C) The conserved CRF1R and GCGR residues involved in TM1-7 and 2-3-4 interface
interactions at the extracellular half of the V-shape open configuration; (D,E). The conserved residues involved in TM2-3 and 3-6-7 interactions at the intracellular half
of the V-shape configuration; (F) GCGR residues Glu 406 of H8 forms an ionic network interacting with TM2 and TM6. Polar contacts are indicated by red (CRF1R) or
black (GCGR) dashes.
involved in interactions with TM 3 and TM6 (Figure 10F), which
may have functional significance.
Ligand Recognition by the Transmembrane
Domain and Druggability of Family B
GPCRs
Although there is no clear universal cognate peptide ligand-
binding site within TMD of family B GPCRs, its location is
suggested to be associated with the TMD (Coopman et al.,
2011; Miller et al., 2011). The crystal structures of CRF1R and
GCGR reveal ligand binding interactions surprisingly deep into
the TMDs with wide binding pockets resulting from the large
distances between extracellular side of TM2 and TM7, and
between that of TM3 and TM7. The deep and wide binding
pockets were not observed in any family A GPCRs.
The highly conserved N-terminal motif of family B peptide
ligands, which precedes the N-capping motif essential in
receptor activation, has been proposed to reach through the
juxtamembrane domain deep into the TMD. Upon interaction,
the helical segment of the extra long TM1 in the juxtamembrane
region is suggested to take a flexible helical structure and thereby
position the N-terminal domain relative to the TMD in favor
of ligand binding. Moreover, the N-capping of the peptide is
suggested to stabilize the receptor-peptide complex (Neumann
et al., 2008; Parthier et al., 2009), which is the second step of
the two-domain binding model, as discussed above in Section
Extracellular Domain: Ligand Binding. Early mutagenesis and
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photoaffinity studies on family B GPCRs including PTH1R,
GLP-1R, and SCTR as well as recent structural studies of CRF1R
and GCGR all provide evidence supporting the deep insertion
(Figures 11A,C; Supplementary Table S1; Liaw et al., 1997; Mathi
et al., 1997; Tseng and Lin, 1997; Di Paolo et al., 1998, 1999;
Hjorth et al., 1998; Cascieri et al., 1999; Xiao et al., 2000; Gardella
and Jüppner, 2001; Solano et al., 2001; Perret et al., 2002; Unson
et al., 2002; Gensure et al., 2003; Runge et al., 2003; Dong
et al., 2004, 2012; Grace et al., 2004; Hoare et al., 2006; Assil-
Kishawi et al., 2008; Ceraudo et al., 2008, 2012; Prévost et al.,
2010; Underwood et al., 2010; Yaqub et al., 2010; Coopman
et al., 2011; Miller et al., 2011; Roberts et al., 2011; Donnelly,
2012; Koole et al., 2012; Koth et al., 2012; Wootten et al.,
2013). For instance, Wright and Rodbell showed that the first six
residues of the glucagon peptide interact with TMD of GCGR
(Wright and Rodbell, 1979). Moreover, mutagenesis studies of
GCGR also showed that mutations deep in the TMD directly
affect glucagon binding, which involved residues Tyr1491.4b,
K1872.60b, Val1912.64b, Gln2323.37b, Glu3626.53b, and Leu3867.43b
(Figure 11; Cascieri et al., 1999; Perret et al., 2002; Unson et al.,
FIGURE 11 | Ligand binding sites of family B GPCRs. (A) Peptide binding pocket of GCGR deep into the TMD. The surface of peptide-binding residues is
color-coded regarding the depth (from purple-shallow to magenta-deep). (B) Mutation studies on effects of peptide binding in GCGR, CRF1R, GIP, GLP-1R, PTH1R,
SCTR, and VPAC1R are mapped on a structure-based sequence alignment. Colored residues show 4–10-fold (pink), and >10-fold (red) effects on Ki/IC50 values for
peptide or ligand potency/EC50 value. The most conserved residues in TM1–7 of family B GPCRs (X.50
b, Figure 10 Box 1) are bolded in orange. Receptor residues
that covalently bind peptide ligands in photo-crosslinking or cysteine-trapping studies are boxed blue. Note that TM regions are not displayed in full length. No
mutagenesis data for residues of TM4 was found and Supplementary Table S1 contains experimental details. (C) The location of CP-376395 in the CRF1R structure is
compared to that of selected family A receptor ligands.
Frontiers in Pharmacology | www.frontiersin.org 13 November 2015 | Volume 6 | Article 264
Culhane et al. Family B GPCR signal transduction
2002; Runge et al., 2003; Prévost et al., 2010; Roberts et al.,
2011; Siu et al., 2013). A full receptor-ligand model of the
glucagon bound GCGR generated by a combination of structural
information of N-terminal domain-ligand complexes and the
recent GCGR transmembrane crystal structure also showed
a similar binding mode (Hollenstein et al., 2014). Moreover,
the results of a series of mutagenesis studies summarized in
Figure 11B provide additional support for the deep binding site
in the TMDs, showing that homologous residues in family B
peptide ligands interact with regions deep into the TMDs.
The relatively large N-terminal regions of family B peptide
ligands may be useful in explaining the wider binding pocket.
In fact, the N-terminus of the CRF peptide that binds CRF1R
is significantly longer than the N-terminus of the glucagon
peptide that binds GCGR (Parthier et al., 2009; Hollenstein et al.,
2014). This may explain the wider pocket in CRF1R around
the extracellular end of TM6, TM7, and extracellular loop 3,
suggesting that the receptors can accommodate large peptide
ligands by positioning the TM helices to form a larger binding
pocket (Hollenstein et al., 2013).
The deep and wide binding pockets revealed by the two
structures also provide new insights into designing molecules to
modulate family B GPCRs. It is worth noting that the crystal
structure of CRF1R in complex with CP-376395 uncovered an
unusual, small-molecule binding pocket that is deep in the
intracellular half of the receptor TMD, over 15 Å away from the
any ligand-binding site in the known family A GPCR structures
(Figures 11A,C; Okada et al., 2004; Cherezov et al., 2007; Chien
et al., 2010; Wu et al., 2010; Shimamura et al., 2011; Hollenstein
et al., 2013). The CP-376395 binding site is defined by TM3,
TM5, and TM6 and features both hydrophobic and hydrophilic
environments that are compatible with drug-like small organic
molecules. It is proposed that CP-376395 acts as an antagonist by
stabilizing the inactive conformation of CRF1R, preventing TM6
from moving away from the center of the TM bundle toward the
membrane, a widely accepted activation mechanism for family
A GPCRs for G protein docking (Bortolato et al., 2014). The
residues in direct contact with CP-376395 in fact show high
sequence identity among family B GPCR (Figures 11B,C), thus
this region can potentially be exploited to design small-molecule
drugs (Cascieri et al., 1999).
Activation and Allosteric Transition
The activation mechanism and transmembrane movements of
family A GPCRs have been extensively studied; however, very
little has been explored in family B GPCRs. As elaborated
by structural and biophysical studies of rhodopsin and other
family A GPCRs (Tehan et al., 2014), the most profound
allosteric transitions include a large outward movement of TM6
(Ballesteros et al., 2001) and the disruption of the ionic lock
between the E/DRY motif on TM3 and acidic residues on
TM6 upon activation (Palczewski et al., 2000; Shapiro et al.,
2002; Kobilka and Deupi, 2007; Yao et al., 2009). In addition,
TM7 bends inward and repositions the tyrosine residue in the
conserved NPxxY motif, which connects to helix 8 to prevent
the reverse movement of TM7 (Prioleau et al., 2002; Fritze et al.,
2003). The bending stabilizes the receptor in an open state. In
this state, TM5 repacks against TM6, opening the interaction
surface for the G protein. These helical movements and switches
provide additional platforms to interact with G proteins. The
outward movement of TM6 creates an interacting pocket for
the C-terminus of Gα. Additional interaction sites of Gα lie
in TM3, TM5, and intracellular loop 2 (ICL2) of the receptor
(Janz and Farrens, 2004; Kobilka and Deupi, 2007; Choe et al.,
2011). Nonetheless, these proposed helical movements found in
family A GPCRs have remained almost unexamined in family B
GPCRs.
Instead of structural and biophysical characterizations, most
studies of transmembrane conformational changes in family B
GPCRs have focused on mutagenesis to identify key residues
and motifs involved in activation (Figure 11B). The structures
of CRF1R and GCGR further confirmed the mutagenesis studies
with a few highly conserved transmembrane motifs that are
potentially important in the activation of family B GPCRs.
First, while GCGR and CRF1R do not have the hallmark ionic
lock between TM3 and TM6 in family A GPCRs, the H-
bonding interaction observed between His2.50b/2.43 on TM2 and
Glu3.50b/3.46 on TM3 may play an equivalent role, breaking upon
activation, which allows outward movements of the helix bundle
(Hollenstein et al., 2013, 2014; Siu et al., 2013). Second, the
conserved NPxxY motif connecting TM7 to the cytoplasmic
helix 8 of family A GPCRs is also missing in family B GPCRs.
However, the tyrosine of that motif is still highly conserved
across family B GPCRs (Figure 8). In fact, in GCGR, Tyr4007.57b
forms hydrogen bonds with residues on TM3 and TM6 and is
positioned in a conformation similar to the conformation in
family A GPCRs that is associated with activation. In CRF1R,
alanine mutations at the equivalent position of Tyr3637.57b shift
the conformation of the receptor toward an inactive state. This
indicates the importance of the conserved tyrosine residue in
TM7 in family B GPCR activation, potentially stabilizing the
receptor in an open and active conformation. These speculated
functions of the conserved residues andmotifs in family BGPCRs
require careful experimental validation.
CYTOPLASMIC DOMAIN: G PROTEIN
COUPLING
Conformational changes in the TMD, as discussed above,
transduce signals from extracellular domains to intracellular
domains, selectively activating various isoforms of G proteins
that trigger specific downstream physiological responses
(bottom, Figure 12; Ritter and Hall, 2009). In this section,
we will review the general model for interaction of GPCRs
and G proteins, emphasizing structural features important for
the interaction in family B GPCRs. We will also discuss the
proposed structural changes within the cytoplasmic regions
upon activation of G proteins.
General GPCR/G Protein Interaction Model
Two models have been proposed for GPCR coupling to G
proteins (Moreira, 2014). These models differ in how and when
GPCRs interact with G proteins. The first one is the collision
model, where GPCRs and G proteins diffuse freely within the
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FIGURE 12 | Interactions of various isoforms of G proteins with the intracellular loops of six family B GPCRs and the downstream signaling pathways
activated by the isoforms. Red indicates Gs, green Gq, gray Gi, yellow Go,and blue G11. Checkered boxes show two G proteins interact with the same loop. The
red box on GLP-1R ICL3 (top left) shows the N-terminal half of the loop associates with Gs and the C-terminal part of the ICL3 associates with Gi.
cell membrane and interact via collision (Gilman, 1987). This
model, however, is not sufficient to explain the rapid response
of many GPCR-mediated pathways, where activation occurs
within milliseconds (Vilardaga et al., 2003). The second model
involves pre-assembled GPCR/G protein complexes that are
formed before ligand binding to receptors. This model has
been increasingly accepted and supported by a few experimental
studies (Galés et al., 2005, 2006; Qin et al., 2011).
While the collision and pre-assembled models are mostly
examined using family A GPCRs (Jastrzebska et al., 2010),
they carry particular significance in understanding signaling
processes of family B GPCRs. On one hand, previous studies
show that the pre-coupling of different G proteins could switch
the ligand selectivity in family B GPCRs and thereby modulates
the receptor’s functions (Ayoub and Pin, 2013). On the other
hand, recent evidence suggests that binding of different native
ligands with a single GPCR can selectively activate different G
proteins. It is currently unknown if the ligand binding influences
the selectivity of coupling to various G proteins in the collision
model, or if the G protein coupling allows the receptor to change
the binding affinity to different ligands in the pre-assembled
model. Thus, examining these two models in family B GPCRs is
important to unravel the intricacy of the signaling processes of
family B GPCRs.
To explore the selectivity in ligands and G proteins for family
B GPCRs, PTH1R has been commonly used as a model system
(Ferrandon et al., 2009). PTH1R contains two native ligands,
PTH and PTHrP. These two ligands share a high degree of
structural and sequential similarities. However, recent FRET
studies demonstrated the two ligands interact with PTH1R
in distinct ways (Ferrandon et al., 2009). While both ligands
bind with similar affinity to PTH1R when the receptor is pre-
assembled with Gs, PTHrP has a lower affinity when the receptor
is not bound to Gs (Hoare et al., 2001; Dean et al., 2008; Okazaki
et al., 2008). Whether this ligand biased signaling is characteristic
of all family B GPCRs requires future studies.
In addition, whether GPCRs function as monomers or
oligomers is important in G protein coupling, but still
controversial. On one hand, GPCRs, except for the family C
members, are proposed to be monomeric and couple to one G
protein after receptor activation (as reviewed in Gurevich and
Gurevich, 2008). On the other hand, recent evidence supports
the idea that GPCRs may function in dimers or higher-order
oligomers (Roed et al., 2012). The oligomeric state of the
receptor might affect the receptor’s ability to couple to and
activate different G proteins, which would lead to activation
of different downstream signaling pathways (Gao et al., 2009;
Harikumar et al., 2012). Although a few studies have used co-
immunoprecipitation, BRET, and FRET to understand GPCR
oligomerization (Roed et al., 2012), the effect of the implicated
oligomerization of family B GPCRs on G protein coupling
requires further examination.
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A detailed structural characterization of the GPCR/G-protein
complex would, of course, provide accurate information about
the interactions between the receptor and G protein. However,
such structures are only available for two family A GPCRs,
rhodopsin and β2 adrenergic receptor (β2AR) (Scheerer et al.,
2008; Choe et al., 2011; Rasmussen et al., 2011; Standfuss
et al., 2011; Deupi et al., 2012; Singhal et al., 2013). These
structures have revealed the importance of ICL2 and ICL3 for
GPCR interactions with the Gα subunit of the heterotrimeric G
proteins (Rasmussen et al., 2011; Ma et al., 2014; Moreira, 2014).
Although family B GPCRs share little sequence similarity with
family A GPCRs in the three cytoplasmic loops, mutagenesis
studies showed the important role of ICL3 in the selectivity and
efficiency of G-protein coupling and activation (Cypess et al.,
1999; Hallbrink et al., 2001; Bavec et al., 2003; Conner et al.,
2006), as detailed below.
Interactions and Structural Changes
Although intracellular loops have been suggested essential for G
protein coupling for family B GPCRs, the specific interactions
that govern the coupling between GPCRs and G proteins vary
from receptor to receptor. Most family B GPCRs can recognize
multiple G proteins, such as Gs, Gq/11, and Gi/o, increasing
the complexity of the signaling processes (Rashid et al., 2004).
Here, we will discuss the key interactions involved in G protein
recognition for the most heavily investigated family B GPCR,
GLP-1R, followed by a summary of the studies for other members
in family B.
Studies of GLP-1R reveal that the coupling of various
G proteins mainly takes place in ICL3 while ICL1 plays a
supplementary role (Figure 12, top). A deletion in ICL3 reveals
that a key block, Lys334-Leu335-Lys336, in theN-terminal region
of this loop is required for coupling to Gs (Figure 12, top left;
Takhar et al., 1996). Moreover, Hallbrink et al. used peptides
to mimic different parts of ICL3 in GLP-1R and concluded
that the N-terminal part of this loop exclusively stimulates Gs
and the C-terminal part exclusively stimulates Gi (Figure 12,
top; Hallbrink et al., 2001). Further studies found mutating
three other amino acids, Val327, Ile328, and Val331, significantly
decrease Gs activation, further corroborating the data showing
that the N-terminal region of ICL3 is involved in Gs activation
(Mathi et al., 1997). In addition to ICL3, ICL1 has also been
shown to participate in Gs coupling, as a single-point mutation
in this region (R176A) is sufficient to significantly reduce cAMP
production (Figure 12, top left; Mathi et al., 1997). ICL1 may
also play an essential role in Gi and Go coupling. Studies using
a chimeric rhodopsin receptor with ICL1 of GLP-1R in the
place of rhodopsin’s ICL3 show the receptor signals through
Gi and Go by coupling with the GLP-1R ICL1 rather than
Gt, the transducin G protein specifically coupled to rhodopsin
(Yamashita et al., 2008). Bavec and coworkers performed a study
to explore how peptides derived from the first, second and
third intracellular loops of GLP-1R differentiate the G protein
signaling pathways. The results suggest that ICL3 is the major
determinant for binding to all G proteins (Gs, Go, Gi, and
G11), whereas the other two intracellular loops are important
in the selectivity of G proteins via modulating the interactions
between ICL3 and G proteins (Figure 12, top; Bavec et al.,
2003).
Studies of other family B GPCRs, including PTH1R, SCTR,
and CGRP receptor, reach similar conclusions that ICL3 is the
key to G protein coupling while ICL1 and ICL2 may also play
subsidiary roles (Figure 12). For PTH1R, the N-terminal region
of ICL3 has been suggested to interact with Gs and Gq (Figure 12,
middle left; Huang et al., 1996) and the C-terminal region of
ICL2, especially the EKKY segment, has been proven important
for Gq coupling (Iidaklein et al., 1997). For SCTR, mutation
studies confirm that at least one residue in ICL1 is involved in
Gq signaling, and that the N-terminal and C-terminal regions of
ICL3 account for Gs and Gq coupling, respectively (Garcia et al.,
2012). For CGRP receptor, mutagenesis studies show that ICL1 is
important for Gs coupling and that theN-terminal region of ICL3
is a key Gs binding motif, while the C-terminal region of ICL3
impairs Gs binding (Figure 12, bottom left; Conner et al., 2006).
For VPAC1R, ICL2 has no observable effect on Gs coupling, but
Lys322 on ICL3 together with another charged residue (Glu394)
on the proximal C-terminal tail of the receptor, play key roles
in coupling with Gs (Figure 12, bottom middle; Langer et al.,
2002). For GCGR, replacement of all or selected intracellular
loops with the ICL1 on D4 dopamine receptor, a family A GPCR,
suggests that ICL2 and ICL3 are required for Gs and Gq coupling
(Figure 12, middle right; Cypess et al., 1999).
As summarized in Figure 12, the general conclusion is that
ICL3 is the key determinant for family B GPCRs to activate
G proteins of all types, including Gs, Gq, Gi/o, and G11. The
specific regions within each receptor that are responsible for
selecting G proteins remain unclear, although accumulating
evidence suggests that the N-terminal portion within ICL3 is
essential for Gs coupling and in some receptors for Gq coupling
as well. However, the selectivity of G proteins can also depend
on the binding of receptors to various ligands and accessory
proteins. Thus, the molecular mechanism behind the selectivity
and activation of G proteins for family B GPCRs is a profound
research topic that requires further exploration.
INTERACTION WITH ACCESSORY
PROTEINS
Aside from G proteins, GPCRs can also associate with a variety
of accessory proteins that play important roles in modulating
receptor functions, including cell surface expression of receptors,
selectivity of hormone ligands, and selection of G protein
signaling pathways (as reviewed in Couvineau and Laburthe,
2012). These accessory proteins are diverse, including but not
limited to receptor-activity-modifying proteins (RAMPs), PDZ
domain-containing proteins, cytoskeleton proteins, chaperone
molecules, and kinases (Couvineau and Laburthe, 2012). In this
section, we will review three representative accessory proteins:
RAMPs, calmodulin (CaM), and Na/H exchange regulatory
factors (NHERFs). We will focus on their role in the signaling
process and the specific sequence motifs responsible for receptor
interactions.
Among the accessory proteins that interact with family B
GPCRs, the RAMP family is the most extensively studied
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(Parameswaran and Spielman, 2006). They have been shown
to dimerize with family B GPCRs, including the calcitonin
receptors, PTH1R, and VPAC1R (Christopoulos et al., 2003;
Archbold et al., 2011). There are three isoforms of RAMPs
(RAMP 1, 2, and 3), which all have a single transmembrane
domain and an 80-amino acid N-terminal domain folded into
three helices (Figures 3, 13; Parameswaran and Spielman, 2006).
The binding interface between RAMPs and family B GPCRs has
not been completely identified. The crystal structure of the CGRP
receptor, a heterodimer of CRLR and RAMP1, shows the binding
interface between N-terminal domains in the extracellular region
of RAMP1 and receptor (Figure 13; ter Haar et al., 2010), where
hydrogen-bonding, hydrophobic, and electrostatic interactions
are key interactions. However, no structural information is
available for interactions between RAMP and the transmembrane
domain or the cytoplasmic domain.
The binding of different RAMP isoforms to family B receptors
can modulate at least three functions of family B GPCRs.
First, the binding of RAMPs regulates receptor trafficking.
For example, the calcitonin receptor (CTR) changes its cell
surface expression upon binding to RAMPs (McLatchie et al.,
1998). Second, the binding of RAMPs can change the G
protein coupling profile. For example, RAMP2 association with
VPAC1R increases Gq coupling without affecting the Gs coupling
(Christopoulos et al., 2003). Finally, RAMPs can switch selectivity
of ligands. For instance, CRLR binds CGRP, amylin peptide
1, and amylin peptide 2 after interacting with RAMP1, 2,
and 3, respectively (Parameswaran and Spielman, 2006). The
mechanism of how RAMPs can bias the ligand binding is
not fully understood; however, several mutagenesis studies of
RAMPs suggested that RAMPs are likely to directly participate
in ligand-GPCR interaction (Qi and Hay, 2010; Archbold et al.,
2011). Nonetheless, it is still unclear at the molecular level how
receptor-RAMP interactions, especially in the transmembrane
and cytoplasmic regions, can modulate the above functions of
family B GPCRs.
Aside from RAMP, another accessary protein, calmodulin,
also interacts with a number of family B GPCRs (Mahon
and Shimada, 2005). Calmodulin is a cytosolic calcium-sensing
protein. It interacts with receptors in a Ca2+-dependent manner
through a consensus CaM-binding motif in the receptors’
C-terminal tails, which is called the basic 1-5-8-14 domain
(Mahon and Shimada, 2005). This binding motif is found in
PTH1R, VPAC11R, PAC1R, CRF1R, CTR, GLP-1R, GLP-2R,
SCTR, and GHRHR (Mahon and Shimada, 2005). Except SCTR
and GHRHR, all these receptors have been shown to bind to
CaM. While Mahon and Shimada showed that the binding
of CaM to PTH1R decreases activation of Gq (Mahon and
Shimada, 2005), the biological functions of CaM still largely
remain unknown.
Another important family of accessory proteins is the four
members of the NHERFs (Ardura and Friedman, 2011). These
proteins are present in the cytoplasm and contain a C-terminal
ezrin-radixin-moesin (ERM)-binding domain and two tandem
PDZ domains (Ardura and Friedman, 2011). The ERM-binding
domain is known to bind ERM proteins, mediating interactions
with actin filaments while the PDZ domain is a common protein
interaction module composed of 80–90 amino-acids found in
signaling proteins that binds to short amino acid motifs of
the C-terminal tail of target proteins (Ardura and Friedman,
2011). The role of PDZ domains of NHERFs is more extensively
studied. This domain recognizes two sequences, of which class I
is important in interactions with family B GPCRs (Ardura and
Friedman, 2011). The class I sequence, ETVM, in the C-terminus
of PTH1R facilitates interactions of the receptor with NHERFs (1
and 2) (Mahon et al., 2002;Mahon and Segre, 2004). The PTH1R-
NHERF interaction not only leads to recruitment of multiple
downstream signaling effectors, but also switches the selectivity
of G protein from Gs to Gq (Mahon et al., 2002; Wang et al.,
2010). Sequence analysis of family BGPCRs suggests the presence
of class I PDZ bindingmotifs in several othermembers, including
VPAC2R, SCTR, GLP-2R, and CRF1R (Couvineau and Laburthe,
2012). However, whether or not these receptors interact with
NHERFs still needs to be examined.
Aside from the above accessory proteins, many other
accessory proteins also interact with family B GPCRs, including
calpain and the 14-3-3 protein, adding complexity to the
signal transduction process of family B GPCRs (Couvineau and
Laburthe, 2012). Indeed, identification of accessory proteins and
investigation of their functional roles is still at the infant stage.
Continuous efforts are necessary to explore the roles of these
accessory proteins in the signaling process of family B GPCRs.
FIGURE 13 | Ligand binding sites in calcitonin receptors likely involve both the receptor N-terminal domain and RAMPs. The crystal structures for the
calcitonin gene related peptide receptor in complex with two small molecule antagonists (blue). The binding pocket for the small molecules is formed by the interface
residues in the two components of the heterodimer: calcitonin receptor-like receptor (CRLR, red) and RAMP1 (ter Haar et al., 2010).
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CHALLENGES AND OUTLOOK
To summarize, this review discusses the current understanding of
the activation mechanism of family B GPCRs focusing on three
steps: (1) ligand binding, (2) transmembrane conformational
changes, and (3) G protein coupling. It also discusses how some
accessory proteins may modulate activation. While the first step
of ligand binding is relatively well understood and described
by the two-domain ligand-binding model, the molecular
mechanism of transmembrane conformational changes, and G
protein coupling have remained largely unknown. Added to this
is the crosstalk among ligands, G proteins, and accessory proteins
with a family B GPCR, which tunes the structure and dynamics
of the receptor and thereby changes the affinity toward different
ligands and activates different isoforms of G proteins. All these
add complexity to the signaling process of family B GPCRs,
making mechanistic studies challenging.
A more complete understanding of the activation mechanism
of family B GPCRs is an urgent need. As shown by mechanistic
studies of family A GPCRs, biophysical characterizations can
be useful: X-ray crystallography (Palczewski et al., 2000; Jaakola
et al., 2008; Choe et al., 2011; Rasmussen et al., 2011; Warne
et al., 2011) and NMR (Ahuja et al., 2009; Smith, 2010)
can determine structures of both inactive and active states,
electron paramagnetic resonance can map patterns of helix
rearrangement during activation (Altenbach et al., 2008), and
other spectroscopic methods, such as fluorescence (Dunham and
Farrens, 1999; Yao et al., 2006), Raman (Pan et al., 2002) and
Fourier-transformed infrared (Fahmy et al., 2000; Mahalingam
et al., 2008) can reveal structures and dynamics of receptors.
Nonetheless, these biophysical characterizations require
purification of full-length, functional family B GPCRs in a
sufficient amount. Many attempts have been made, ranging from
purification from natural sources to heterologous expression
systems, such as E. coli, mammalian cells, insect cells, and cell-
free synthesis systems. So far, only three out of the many studies
have shown functional, purified receptors can bind to the ligand
and activate G proteins (Ohtaki et al., 1998; Shimada et al., 2002;
Mitra et al., 2013). In addition, few studies perform biophysical
studies on purified receptors to understand the conformational
and dynamic changes during activation.
Recently, our laboratory developed a purification method for
family B GPCRs, which directly purifies GPCRs into nanodiscs—
disc-shaped particles containing a single layer of lipid bilayer
that is stabilized by two membrane scaffold proteins (Mitra
et al., 2013). This method reduces the contact of a receptor with
detergent and eliminates the step of reconstitution of receptor
from detergent solubilized environment into lipid bilayers.
The receptor then has both the extracellular and cytoplasmic
domains exposed to solution, enabling assessment of molecular
interactions from both sides (Leitz et al., 2006; Banerjee et al.,
2008; El Moustaine et al., 2012; Inagaki et al., 2012). Unlike
detergent systems, nanodiscs can stabilize receptors without
the presence of extra micelles that results from maintaining a
detergent concentration above the critical micelles concentration
(CMC). Thus, the use of nanodiscs in stabilization of receptors
can reduce backgrounds in biophysical measurements, such as
light scattering in optical spectroscopy or detergent signals in
NMR experiments. Hence, the nanodisc system can provide
flexibility in designing biophysical experiments (Serebryany
et al., 2012), highlighting it as an ideal platform for molecular
biophysical characterizations.
Aside from structure-function correlation, the dynamics
of the molecular mechanism of family B GPCRs remain
largely unknown and unexplored. While solution NMR and
single-molecule spectroscopy are commonly used to study
protein dynamics, they are not commonly applied to GPCRs.
The advancement in computational biology and molecular
modeling is deepening our understanding of molecular dynamics
(Singh et al., 2015). However, this requires building reliable
models for full length family B GPCRs, which is challenging.
Even though the transmembrane domain structures of two
family B receptors became available, determining the relative
orientations of the N-terminal domain and the transmembrane
domain remains a difficult task, which requires a synergistic
experimental and computational approach. A few groups are
working toward building computational models of full-length
family B GPCRs, specifically for SCTR, GLP-1R, and PTH1R
(Thomas et al., 2008; Coopman et al., 2011; Dong et al.,
2011a; Kirkpatrick et al., 2012). These models still require
experimental studies of full-length receptors for verification and
refinement.
In addition, development of drugs targeting family B GPCRs
is still challenging in at least two ways: (1) peptide ligand
derivatives as drugs suffer from rapid renal clearance and
proteolytic degradation; (2) small molecules as drugs are hard
to identify due to limited structural information. There are thus
considerable efforts drawn to improve the efficacy of peptide-
based drugs (Zuckermann and Kodadek, 2009; Denton et al.,
2013; Johnson et al., 2014; Liu et al., 2015); and the current
advances in structural biology, especially the crystal structure
of small-molecule docked CRF1R’s transmembrane, will shed
light on rational design of small molecules targeting family B
GPCRs.
A theme that runs through this review is the complexity of
the signaling processes of family B GPCRs, which comes from
modulations of family B GPCRs by ligands, G proteins,
and accessory proteins. These modulations change the
selectivity of the receptors during ligand sensing and G
protein coupling, greatly enriching the information content of
cellular communication with the environment and the cellular
response to the hormone signaling processes. The field of family
B GPCRs is beginning to understand that the signaling process is
not only through interactions of a receptor with a specific pair
of a ligand and a G protein but also global changes in receptor
structure and dynamics regulated by simultaneous and/or
sequential interactions with ligand, G proteins, and accessory
proteins. A complete understanding of the molecular mechanism
of GPCR activation will continue to require a collaborative effort,
from high-resolution structural determinations and quantitative
biophysical characterizations, to cellular studies of signaling
processes and computational molecular modeling, in order to
reveal the underlying activation mechanism of family B GPCRs
at the fundamental level.
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